Published in Acta Oncol on January 01, 2002
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Can Urol Assoc J (2013) 0.94
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist (2016) 0.83
Neoadjuvant chemotherapy for bladder cancer. World J Urol (2006) 0.80
Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder. Indian J Urol (2011) 0.75
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol (2006) 2.64
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol (2009) 2.13
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol (2008) 2.06
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol (2005) 2.01
Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res (2007) 1.87
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol (2008) 1.74
Retroperitoneal soft tissue sarcomas: a treatment challenge and a call for randomized trials. Radiother Oncol (2002) 1.65
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol (2002) 1.61
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol (2006) 1.49
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol (2007) 1.43
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst (2002) 1.34
High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res (2005) 1.34
Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer (2006) 1.15
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer (2010) 1.13
Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol (2004) 1.12
Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother (2004) 1.12
The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol (2007) 1.10
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res (2006) 1.09
Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol (2002) 1.08
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat (2008) 1.04
Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. Int J Radiat Oncol Biol Phys (2004) 1.03
Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res (2009) 1.02
Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol (2014) 1.02
Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol (2010) 1.02
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol (2002) 0.96
Cosmetic outcome and breast morbidity in breast-conserving treatment--results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol (2002) 0.96
Prognosis in patients with symptomatic metastatic spinal cord compression: survival in different cancer diagnosis in a cohort of 2321 patients. Spine (Phila Pa 1976) (2013) 0.96
Early and late treatment-related morbidity following radical cystectomy. Scand J Urol Nephrol (2004) 0.95
Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncol (2011) 0.94
Pseudosarcomatous fibromyxoid tumor of the prostate. Scand J Urol Nephrol (2003) 0.93
High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. Genes Chromosomes Cancer (2012) 0.91
Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc (2009) 0.90
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer (2005) 0.90
Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol (2009) 0.89
Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res (2005) 0.88
Postpartum urinary incontinence. Acta Obstet Gynecol Scand (2003) 0.87
Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncol (2011) 0.87
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med (2013) 0.85
Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl (2010) 0.85
Microbial flora in ileal and colonic neobladders. Eur Urol (2004) 0.84
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol (2005) 0.84
Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol (2004) 0.84
Complications and neobladder function of the Hautmann orthotopic ileal neobladder. BJU Int (2006) 0.84
Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol (2011) 0.82
Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer. Int J Gynecol Cancer (2012) 0.81
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer (2010) 0.81
A closer look at RapidArc® radiosurgery plans using very small fields. Phys Med Biol (2011) 0.81
Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol (2002) 0.81
Relative importance of sources of symptom-induced distress in urinary bladder cancer survivors. Eur Urol (2003) 0.80
Sentinel lymph-node biopsy in patients with squamous cell carcinoma of the penis. BJU Int (2009) 0.80
Positron emission tomography/computed tomography in the staging and treatment of anal cancer. Int J Radiat Oncol Biol Phys (2011) 0.80
Fear of recurrence and causal attributions in long-term survivors of testicular cancer. Psychooncology (2011) 0.79
Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin Cancer Res (2004) 0.79
Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol (2006) 0.79
Urethral pressure reflectometry; a novel technique for simultaneous recording of pressure and cross-sectional area: a study of feasibility in the prostatic urethra. BJU Int (2012) 0.79
Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol (2004) 0.78
Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. Scand J Urol (2014) 0.78
Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. Cancer Immunol Immunother (2004) 0.78
Transitional cell bladder tumor: predicting recurrence and progression by analysis of microsatellite loss of heterozygosity in urine sediment and tumor tissue. Cancer Genet Cytogenet (2006) 0.78
Screening for Y microdeletions in men with testicular cancer and undescended testis. J Assist Reprod Genet (2006) 0.78
Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J Mol Diagn (2010) 0.77
The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database. Acta Oncol (2014) 0.77
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. J Immunother (2007) 0.77
Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol (2005) 0.77
A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer. Acta Oncol (2010) 0.77
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int (2008) 0.77
Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol (2004) 0.76
Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Res Treat (2011) 0.76
Anal Cancer debuting as Cancer of Unknown Primary. Rare Tumors (2011) 0.76
Serum lactate dehydrogenase isoenzyme 1 in patients with seminoma stage I followed with surveillance. Acta Oncol (2002) 0.76
[Cystectomy in Denmark 2001-2005]. Ugeskr Laeger (2008) 0.75
Precursor lesions in testis and dysgenetic gonads. Hum Pathol (2006) 0.75
Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol (2005) 0.75
[The Folkman effect 2]. Ugeskr Laeger (2005) 0.75
Carbon calculations to consider. Science (2010) 0.75
Plagiarism criteria ignore the way research evolves. Nature (2005) 0.75
[Urinary bladder cancer]. Ugeskr Laeger (2002) 0.75
New evaluation of plasma DNA microsatellite analysis in patients with TCC of the urinary bladder. Anticancer Res (2004) 0.75
[Treatment of invasive bladder cancer]. Ugeskr Laeger (2008) 0.75
[Canine cancer patients are included in translational research]. Ugeskr Laeger (2014) 0.75
Prognostic factors, pattern of recurrence and survival in a Danish bladder cancer cohort treated with radical cystectomy. Acta Oncol (2003) 0.75
[Immunotherapy of cancer]. Ugeskr Laeger (2002) 0.75
Microsatellite analysis of urine sediment versus urine cytology for diagnosing transitional cell tumors of the urinary bladder. APMIS (2004) 0.75
[Malignant skin melanoma]. Ugeskr Laeger (2002) 0.75
Moderate precision of prognostic scoring systems in a consecutive, prospective cohort of 544 patients with metastatic spinal cord compression. J Cancer Res Clin Oncol (2014) 0.75